Medpace Holdings, Inc. (NASDAQ: MEDP)

Medpace Holdings, Inc. is a leading global contract research organization that provides outsourced clinical development services to biotechnology pharmaceutical and medical device companies.

The company generates revenue by offering a full suite of services that support the entire clinical development process from Phase I through IV across many therapeutic areas including oncology metabolic cardiology antiviral and anti infective and central nervous system research. It earns fees for activities such as study design site management patient recruitment data handling regulatory submissions and other related support functions.

Medpace Holdings Inc ranks among the top contract research organizations by revenue worldwide. It competes with large full service CROs such as IQVIA Holdings Inc ICON plc PPD (now part of Thermo Fisher Scientific) and Fortrea Inc as well as many niche providers. Its competitive advantages stem from a fully integrated service model deep therapeutic expertise in areas like oncology metabolic cardiology antiviral and anti infective and central nervous system research and a global delivery platform that enables rapid patient enrollment and high quality data collection. The disciplined operating model and experienced management team further strengthen its market position.

The company serves a diverse client base that includes small mid sized and large biopharmaceutical firms as well as medical device manufacturers.